TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
21.43
+0.16 (+0.75%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close21.27
Open21.37
Bid21.32 x 1000
Ask21.52 x 4000
Day's Range21.31 - 21.76
52 Week Range10.85 - 25.96
Volume4,090,659
Avg. Volume11,935,232
Market Cap21.822B
Beta (3Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-10.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-27
1y Target Est21.53
Trade prices are not sourced from all markets
  • Stephanie Link's big buy in final trades
    CNBC Videos4 days ago

    Stephanie Link's big buy in final trades

    Tech, healthcare and a whale - should you own these stocks?

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
    Zacks14 hours ago

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed at $21.45 in the latest trading session, marking a +0.85% move from the prior day.

  • A Performance Overview of JNJ’s Beauty and OTC Businesses
    Market Realist17 hours ago

    A Performance Overview of JNJ’s Beauty and OTC Businesses

    Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.

  • GlobeNewswire22 hours ago

    New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • What Are Pfizer’s Revenue Drivers?
    Market Realist2 days ago

    What Are Pfizer’s Revenue Drivers?

    Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.

  • Reuters3 days ago

    Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
    Reuters3 days ago

    Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
    Investing.com3 days ago

    Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises

    Investing.com - Stocks in focus in pre-market trade Wednesday:

  • Regeneron's Dupixent Meets Goals in Nasal Polyps Studies
    Zacks3 days ago

    Regeneron's Dupixent Meets Goals in Nasal Polyps Studies

    Regeneron's (REGN) atopic dermatitis drug, Dupixent meets goals in two late-stage studies for nasal polyps.

  • CNBC3 days ago

    Stocks making the biggest move premarket: NFLX, IBM, CSX, UAL, TEVA & more

    Check out the companies making headlines before the bell: Netflix NFLX – Netflix reported quarterly profit of 89 cents per share , easily beating the consensus estimate of 68 cents a share. Revenue was in line with Street forecasts, and the important metric of net subscriber additions was well above analysts' expectations for the video streaming service.

  • A Financial Overview of Bausch Health in October
    Market Realist8 days ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

  • How Analysts View Bausch Health in October
    Market Realist8 days ago

    How Analysts View Bausch Health in October

    In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.

  • Reuters8 days ago

    U.S. appeals court upholds ruling that canceled Teva Copaxone patents

    A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. The ruling was a victory for a group of generic drug companies, including Mylan NV and Novartis AG unit Sandoz, that challenged the validity of Teva's patents in order to sell generic versions. Teva did not immediately respond to requests for comment.

  • Investor Insights: Teva Pharmaceutical’s Valuation Multiples
    Market Realist9 days ago

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.

  • Analysts Raised Their Recommendations on Teva Stock in October
    Market Realist9 days ago

    Analysts Raised Their Recommendations on Teva Stock in October

    Leerink raised its recommendation on Teva Pharmaceutical Industries from “underperform” to “market perform.” The firm also raised its target price from $16 to $24 on October 1. The stock registered a rise of ~3.6% during premarket trading on the day. Teva has strong fundamentals that have been improving recently due in part to the more stable generics pricing environment in the United States.

  • Wall Street Analysts See Upside Potential of 3.9% in TEVA
    Market Realist9 days ago

    Wall Street Analysts See Upside Potential of 3.9% in TEVA

    Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.

  • Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
    Zacks9 days ago

    Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing

    Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.

  • Business Wire9 days ago

    Teva Draws on Patient Experience to Empower Those Living with Chronic Conditions

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. With content developed in collaboration with patients, Life Effects consists of articles, videos and podcasts that offer information, insight and inspiration to people suffering from one or more chronic condition, including MS, particularly focusing on the impact a condition has on a patient’s day-to-day life. By working with a core group of patients on an ongoing basis, who make direct contributions which are reviewed by experts, Life Effects offers a first-hand, credible perspective on what it’s like to live with a chronic condition.

  • 5 “Warren Buffett Stocks” That Might Not Be His Ideas
    Kiplinger10 days ago

    5 “Warren Buffett Stocks” That Might Not Be His Ideas

    Warren Buffett is one of the most successful investors (if not the most) of all time, and chief stock-picker for Berkshire Hathaway (BRK.B). Since assembling the group of companies that would eventually become Berkshire back in 1964, the so-called Oracle of Omaha's baby has trounced the broad market's return. That has led the market to hunt down so-called "Warren Buffett stocks" in hopes of benefitting from his wisdom and discipline. But Buffett, at 88 years of age, already has had to step away from complete control of Berkshire Hathaway, unable to keep up the pace of study needed to keep his fund's holdings optimized. Other acolytes have emerged, and out of necessity have started making stock picks for Berkshire without necessarily requiring Buffett's blessing. Todd Combs and Ted Weschler are at least running a big part of the show. Their selections aren't always divulged as non-Buffett picks. From a shareholder's perspective, Berkshire and its collective chiefs are one and the same, and reported as such. It's sometimes quite clear, though, that Warren Buffett had little-to-nothing to do with a particular holding. Here are five Berkshire Hathaway holdings that might not necessarily be "Warren Buffett stocks." That's because they're out of character with the decades' worth of insight and tips he's been willing to dish out. More importantly: They might give us clues as to the direction of Berkshire's picks once Buffett is completely out of the picture. SEE ALSO: How Well Do You Really Know Warren Buffett?

  • Business Wire10 days ago

    Celltrion and Teva Announce FDA Oncologic Drugs Advisory Committee Recommends Approval of Celltrion BLA for CT-P10, a Proposed Rituximab Biosimilar

    Celltrion, Inc. (068270.KS) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan®1 (rituximab) for the treatment of adult patients in three proposed indications.

  • Business Wire10 days ago

    Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE® (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis

    The extension study initially examined the safety of COPAXONE® 20 mg/mL daily and then also the 40 mg/mL three times weekly formulation when it became available approximately 20 years later. Patients who participated in the original 36-month, randomized placebo-controlled U.S. trial were eligible to proceed to the open-label extension, in which patients receiving COPAXONE® continued their treatment, while those who received placebo were switched to COPAXONE®. Results show that for study patients who continued to take COPAXONE®, long-term treatment has an acceptable safety and tolerability profile with low rates of serious adverse events (SAEs) and immediate post-injection reactions (IPIRs).

  • Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low
    Market Realist11 days ago

    Mylan Stock Falls on Analyst Downgrade, Trades at 52-Week Low

    Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36. Also, Mylan has seen lower-than-expected sales from its biosimilar and complex products portfolio, which it’s increasingly focusing on in the wake of increasing generics competition and pricing pressures. Today, MYL stock fell ~2.7% during premarket trading.

  • Benzinga11 days ago

    3 Headwinds Hindering Mylan

    Even with positive near-term catalysts, Mylan NV (NASDAQ: MYL ) suffers from “uncertain prospects” that warrant a neutral stance, according to Morgan Stanley.  The Rating Analyst David Risinger downgraded ...

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist11 days ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • Business Wire12 days ago

    Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin

    Teva Pharmaceutical Industries Ltd. today announced that new data on COPAXONE® , a product for relapsing forms of multiple sclerosis , will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, October 10-12, 2018.